

## ASMS 2017 MP-713

Alan Barnes<sup>1</sup>; Tiphaine Robin<sup>2</sup>; Sylvain Dulaurent<sup>2</sup>; Souleiman Elbalkhi<sup>2</sup>; Stéphane Moreau<sup>3</sup>; Neil Loftus<sup>1</sup>; Pierre Marquet<sup>2</sup>; Franck Saint-Marcoux<sup>2</sup> <sup>1</sup>Shimadzu, Manchester, UK; <sup>2</sup>CHU Limoges, Limoges, France, <sup>3</sup>Shimadzu Europa GmbH, Duisburg, NRW.

PO-CON1765E

## Introduction

A library of product ion spectra for 1222 compounds has been developed for clinical and forensic toxicology screening to help reduce false positive and false negative reporting. The library enables multi-targeted methods to be developed for routine screening, library identification and quantitation.

The scope of the library considers two approaches; a MRM triggered full scan product ion spectra and MRM

Spectrum mode. MRM Spectrum mode acquires a high number of fragment ion transitions for each target compound generating a fragmentation spectra which can be used in routine library searching and compound verification using reference library match scores. In this work, MRM Spectrum mode has been applied to analysis of patient samples to quantify and identify targets in whole blood samples extracted using a QuEChERS method.

## Methods and Materials

Whole blood was spiked with target compounds and extracted with a QuEChERS method protocol (where possible deuterated internal standards were also included). Chromatographic conditions considered a diverse chemical space to create a generic single method approach for clinical and forensic toxicology screening with a cycle time of 17minutes.

Liquid chromatography			
UHPLC Analytical column Column temp. Injection cycle Flow rate Solvent A Solvent B	<ul> <li>Nexera LC system</li> <li>Restek Raptor Biphenyl</li> <li>2.7um 100 x 2.1mm</li> <li>50°C</li> <li>5 μL injection volume</li> <li>0.3 mL/min</li> <li>Water + 2mM ammonium formate + 0.002% formic acid</li> <li>Methanol + 2mM ammonium formate + 0.002% formic a</li> </ul>		
Binary Gradient	Time (mins)	%B	]
	1.00	5	-
	2.00	40	-
	10.50	100	-
	13.00	100	-
	13.01	5	-
	17.00	Stop	-
	11-14.2	0.5 mL/min	-
Mass spectrometry			
LC-MS/MS	: LCMS-8060		
Ionisation mode	: Heated ESI		
Scan speed	: 15,000 u/sec		
Polarity switching time	: 5 msec		
MRM Dwell time	: 1 msec		
Pause time	: 1 msec		
Interface temp.	: 300°C		
Heating block	: 400°C		
Desolvation line	: 250°C		
Heating gas	: 10 L/min		
Drying gas	: 10 L/min		
Nebulising gas	: 3 L/min		
CID gas pressure	: 250kPa		
Interface voltage	: 4 kV		

Table 1. LC-MS/MS data acquisition conditions.

### Clinical and forensic library

The spectral library contains information on 1222 clinical and forensic toxicological compounds with libraries for both full scan product ion spectra and MRM product ion spectra data. The MRM Spectrum mode library includes product ion spectra created by combining typically more than 5 precursor-fragment ion transitions for each compound, each precursor-fragment ion transitions has an optimized collision energy resulting in a specific product ion spectra and a high signal intensity. The database also includes structure (as a mol file), RT, CAS number, formula, synonyms, compound class/properties, ChemSpider URL and ID number, InChI and InChIKey. The key advantages of this approach include its simplicity to set up a method and adapt to other needs, high data densities, consistent loop time and a high sampling rate producing reliable quantitation and peak integration without the need to use a predefined a threshold.

## Results

2 -

0 -

100

200

### MRM Spectrum mode | Quantitation

Conventional guantitative data acquisition by triple guadrupole LC-MS/MS typically uses 2 MRM per compound; MRM Spectrum mode acquires a higher number of precursor-fragment ion transitions to generate a library searchable product ion spectrum.



v = 0.02647097x - 0.07608868

400

300

Concentration (ug/L)

 $R^2 = 0.9949689$ 

y = 0.02647097x - 0.07608868; R<sup>2</sup> = 0.9949689 2 MRM regression analysis

OH

 $y = 0.02561410x - 0.002689508; R^2 = 0.9996442$ 

Figure 1. One example of a target compound (in this case benzoylecgonine) acquired by MRM Spectrum mode. In this method a higher number of precursor- fragment ions were monitored to generate a MRM product ion spectrum (for each compound in the screening method up to 6 MRM's were monitored).

Table 2. Quantitative comparison of the same patient sample measured by a conventional validated 2 MRM method (CHU Limoges) and MRM Spectrum mode using different LC-MS/MS instruments (the 2 MRM data was generated on a LCMS-8050). Both data sets are in close agreement.

Compound	RT (min)	CHU-Limoges	MRM-Spectrum mode
		Patient sample	Patient sample
Morphine	3.32	>500	>500
Benzoylecgonine	4.64	>500	>500
EDDP	7.52	>500	>500
Methadone	8.16	116	127
Ecgonine methylester	1.05	73	72
Hydromorphone	3.48	35	31

### MRM Spectrum Mode Results | patient sample

As part of the evaluation, patient sample data was acquired using MRM Spectrum mode to quantify and identify targets.

#### Screening analysis Unknown psychiatric patient sample Whole blood sample; QuEChERS extraction; Restek Raptor Biphenyl 2.7um 100 x 2.1mm MRM library for confirmation.



Figure 2. MRM chromatograms are shown for norbuprenorphine, buprenorphine, oxazepam, nordiazepam and temazepam from a psychiatric patient sample.

180

200

220

240

260

# Toxicological screening for over 1000 compounds in an MRM based acquisition for Library ID in whole blood samples





#### Nordiazepam MRM Spectrum Similarity Score 99

**Buprenorphine MRM Spectrum** 



Figure 3. Psychiatric patient sample analysis detected norbuprenorphine, buprenorphine, oxazepam, nordiazepam and temazepam using MRM Spectrum mode. The product ion spectrum can be used for compound identification by searching a library. As the collision energy was optimized for each fragment ion to generate a product ion spectrum, the library spectrum is highly specific and selective.

280 m/z



### MRM Spectrum mode | CAO panel identification

Patient sample data was acquired using MRM Spectrum mode to quantify and identify targets in a CAO panel.

Compound

#### **Screening analysis**

RT 1.035 mins

Concentration 78.3ug/L

**Identification score 97** 

200.15>182.10 CE-17V

200.15>82.05 CE-25V

200.15>150.10 CE-20V

200.15>83.10 CE-30V

200.15>91.05 CE-32V

Unknown sample; request for CAO panel analysis

Whole blood sample; QuEChERS extraction; Restek Raptor Biphenyl 2.7um 100 x 2.1mm 44 target compounds (including 21 internal standards); MRM library for confirmation.

Compound Econonine methylester

Benzoylecgonine RT 4.635 mins Concentration 574.8ug/L Identification score 99 290.15>168.15 CE-18V 290.15>77.00 CE-54V 290.15>105.05 CE-28V 290.15>82.10 CE-28V 290.15>150.10 CE-23V **Compound Morphine** RT 3.312 mins Concentration1384.1ug/L **Identification score 100** 286.15>152.10 CE-59V 286.15>201.10 CE-26V 286.15>165.10 CE-37V



Compound Methadone RT 8.158 mins Concentration 112.1ug/L Identification score 99 290.15>168.15 CE-15V 290.15>77.00 CE-26V 290.15>105.05 CE-53V 290.15>82.10 CE-21V 290.15>150.10 CE-22V

0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 min

Figure 4. Patient sample analysis for CAO panel of drugs. MRM chromatograms are shown for ecgonine methylester, benzoylecgonine, morphine, EDDP and methadone.

286.15>128.05 CE-58V

286.15>153.10 CE-41V



Figure 5. MRM product ion spectra and library similarity scores for ecgonine methylester, benzoylecgonine, morphine and methadone in a patient blood sample.

## Conclusions

• MRM Spectrum mode results in high data densities and a high data sampling rate across a peak. This approach generates a consistent loop time and sampling rate producing reliable guantitation and peak integration without threshold triggering and creates new opportunities in toxicological screening.

Disclaimer: The Shimadzu LCMS-8060 is intended for Research Use Only (RUO). Not for use in diagnostic procedures. Not available in China.



Shimadzu Corporation

www.shimadzu.com/an/

#### For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®".

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "@". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.